2014
DOI: 10.1111/cbdd.12295
|View full text |Cite
|
Sign up to set email alerts
|

A Bifurcated Proteoglycan Binding Small Molecule Carrier for siRNA Delivery

Abstract: A wider application of siRNA- and miRNA- based therapeutics is restricted by the currently available delivery systems. We have designed a new type of small molecule carrier (SMoC) system for siRNA modeled to interact with cell surface proteoglycans. This bifurcated SMoC has similar affinity for the model proteoglycan heparin to an equivalent polyarginine peptide and exhibits significant mRNA knockdown of protein levels comparable to lipofectamine and the previously reported linear SMoC.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
13
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 14 publications
(14 citation statements)
references
References 31 publications
1
13
0
Order By: Relevance
“…Another interesting study, primarily germane to muscle tissue, found that the clinically utilized drug dantrolene improved the effects of SSOs that correct dystrophin expression in a model of Duchennne muscular dystrophy [148]; however the precise mechanism of action is unclear. Yet another study demonstrated increased delivery of siRNA using guanidine-like small molecules that complex with the siRNA and that may also bind to cell surface proteoglycans to improve cell uptake [149]. A recent conference proceeding [150] described a small molecule, Guanabenz, that also complexed with siRNA and enhanced uptake and effects in cell culture.…”
Section: Endocytosis and Trafficking Of Oligonucleotidesmentioning
confidence: 99%
“…Another interesting study, primarily germane to muscle tissue, found that the clinically utilized drug dantrolene improved the effects of SSOs that correct dystrophin expression in a model of Duchennne muscular dystrophy [148]; however the precise mechanism of action is unclear. Yet another study demonstrated increased delivery of siRNA using guanidine-like small molecules that complex with the siRNA and that may also bind to cell surface proteoglycans to improve cell uptake [149]. A recent conference proceeding [150] described a small molecule, Guanabenz, that also complexed with siRNA and enhanced uptake and effects in cell culture.…”
Section: Endocytosis and Trafficking Of Oligonucleotidesmentioning
confidence: 99%
“…Stable plasma membrane association could be a result of hsiRNA charge shielding via a non-covalent RNA-Guanabenz interaction. Indeed, the highly basic guanidinium moiety is analogous to an arginine side-chain, a feature commonly observed in cationic cell-penetrating peptides such as the HIV-derived TAT peptide or the non-viral penetratin ( 16 , 22 ). The observed impact on the level of hsiRNA cellular association is specific to early time points, as overall level of internalized oligonucleotides equilibrates by 24 h with no significant alteration in co-localization with lysosomal markers (Figure 3B ).…”
Section: Resultsmentioning
confidence: 99%
“…First, Gooding et al . have reported the synthesis of small molecule carriers (SMoC) of siRNA, which form non-covalent electrostatic interactions with unmodified siRNA to enhance plasma membrane translocation ( 16 , 17 ). Second, Juliano's group demonstrated that the small molecule Retro-1, which is involved in retrograde transport of bacterial toxins, appreciably improved the activity of nuclear-localized ASOs following simultaneous transfection.…”
Section: Introductionmentioning
confidence: 99%
“…The authors hypothesised that in the presence of lipid membranes, the carrier structure was able to unfold allowing the hydrophobic porphyrin to be inserted into the lipid membrane. PCI could similarly be applied to the delivery of small molecule carrier systems (SMoC) in the delivery of siRNA or miRNA …”
Section: Cytotoxic Agents Used With Pcimentioning
confidence: 99%
“…PCI could similarly be applied to the delivery of small molecule carrier systems (SMoC) in the delivery of siRNA or miRNA. 57…”
Section: Macromolecular Drug Carriersmentioning
confidence: 99%